Summit Therapeutics’ (SMMT) latest tweak to its clinical playbook has turned what was already one of biotech’s higher‑stakes stories into something closer to appointment viewing for Wall Street.
A Phase 3 Trial Adds a Plot Twist
Summit now plans an interim progression‑free…